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REVIEW ARTICLE OPEN
Presentation of lung cancer in primary care
D. P. Weller1, M. D. Peake2 and J. K. Field3
Survival from lung cancer has seen only modest improvements in recent decades. Poor outcomes are linked to late presentation,
yet early diagnosis can be challenging as lung cancer symptoms are common and non-speciﬁc. In this paper, we examine how lung
cancer presents in primary care and review roles for primary care in reducing the burden from this disease. Reducing rates of
smoking remains, by far, the key strategy, but primary care practitioners (PCPs) should also be pro-active in raising awareness of
symptoms, ensuring lung cancer risk data are collected accurately and encouraging reluctant patients to present. PCPs should
engage in service re-design and identify more streamlined diagnostic pathways—and more readily incorporate decision support
into their consulting, based on validated lung cancer risk models. Finally, PCPs should ensure they are central to recruitment in
future lung cancer screening programmes—they are uniquely placed to ensure the right people are targeted for risk-based
screening programmes. We are now in an era where treatments can make a real difference in early-stage lung tumours, and
genuine progress is being made in this devastating illness—full engagement of primary care is vital in effecting these
improvements in outcomes.
npj Primary Care Respiratory Medicine           (2019) 29:21 ; https://doi.org/10.1038/s41533-019-0133-y
INTRODUCTION
Lung cancer poses a signiﬁcant public health burden around the
world; it is the most common cause of cancer mortality in the UK
and it accounts for >20% of cancer deaths.1 There is signiﬁcant
variation in survival rates around the world and this has been
largely attributed to the stage at which the cancer is diagnosed.2
The International Cancer Benchmarking Partnership has demon-
strated that survival rates in the UK lag behind those of other
countries, and late diagnosis is thought to be a major underlying
factor.3,4 Importantly, patients with early-stage disease have a
much better prognosis; stage 1 non-small-cell lung cancer can
have a 5-year survival rate as high as 75%.5 Even within the UK,
however, there is wide variation in lung cancer survival rates and
in the proportion of patients diagnosed with early-stage disease.6
In the UK, most cancers present symptomatically in primary care
(most commonly to a general practitioner, or ‘GP’, the medical
lead of a primary care team), and the diagnosis is made after a
referral for either investigations or directly to secondary care.7
Many of the symptoms of lung cancer are very common but non-
speciﬁc in primary care practice: these include chest pain, cough
and breathlessness;8 hence, lung cancer poses a very signiﬁcant
diagnostic challenge—a primary care practitioner (PCP) working
full time is likely to only diagnose 1 or 2 cases per year. Further,
lung cancer often emerges on a background of chronic respiratory
disease and symptoms of chronic cough—typically in patients
who smoke. It can be very difﬁcult to identify changes in these
chronic symptoms that might indicate the development of a lung
tumour.
Smoking remains the principal aetiological factor and smoking
cessation is the key public health initiative to reduce mortality
from this disease;9 indeed, at almost any age smoking cessation
can produce health beneﬁts. Hence, public health campaigns to
promote smoking cessation, supplemented by strategies in
primary care based on nicotine replacement therapies should be
encouraged.10 The role of e-cigarettes is not yet fully under-
stood,11 although any strategy that reduces exposure to tobacco
smoke has a potential for producing signiﬁcant beneﬁts.
HOW DO PATIENTS RESPOND TO LUNG CANCER SYMPTOMS?
There is a signiﬁcant body of research around patient response to
symptoms that might potentially indicate lung cancer. Because
symptoms often present within the context of chronic respiratory
symptomatology, changes associated with the development of a
tumour may go un-noticed or be dismissed.8 It is known that
patients often delay their help seeking through a range of
psychological mechanisms including denial and nihilism—hence,
there can often be signiﬁcant delays before patients present to
primary care.12,13
There is evidence for variation in the timeliness of presentation
of lung cancer in between countries; people with lung cancer
often have symptoms for a considerable period of time before
they present to primary care and this is a major source of delay in
the diagnostic process with potential adverse impact on
survival;14,15 this patient interval does, however, vary between
studies. It is important that PCPs understand some of the
psychological mechanisms that either promote or inhibit early
presentation among their patients.
PUBLIC AWARENESS OF LUNG CANCER
Over the past few years, there have been campaigns run
throughout the UK designed to make the public more aware of
symptoms associated with lung cancer—for example the ‘Be clear
on Cancer’ campaign run by Public Health England and ‘Diagnose
Cancer Early’ in Scotland16,17 (see Fig. 1). These campaigns have
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demonstrated an ability to diagnose additional cancers and effect
modest increases in the proportion of patients having tumours
diagnosed at stages where they are amenable to resection.18,19
Of course, lung cancer early detection programmes need to be
focussed on the hard-to-reach population and those who will
beneﬁt most from involvement; there are often concerns
expressed over burdening services with patients with insigniﬁcant
symptoms18 and an emerging consensus that all stakeholders
should be closely engaged in the campaigns. Nevertheless,
available evidence suggests that lung cancer could be diagnosed
earlier through these public awareness campaigns,19 particularly
when associated with systems to help primary care physicians risk
stratify their patients for lung cancer more effectively—indeed,
further work to identify patients who might beneﬁt from targeted
interventions should be a priority.
Community-based social marketing interventions have a
potential key role;20 they can increase the likelihood of patients
attending PCPs and increase primary care diagnostic activity (such
as chest X-ray referrals)—as well as increases in lung cancer
diagnostic rates. The level of suspicion at which PCPs consider a
referral is a key factor in response to these campaigns—and there
are concerns over ‘system overload’ through encouragement to
present with symptoms.13 Ideally, campaigns might preferentially
target those at greater risk of lung cancer, such as people with
signiﬁcant smoking histories or occupational exposure.
PRIMARY CARE RESPONSE TO LUNG CANCER SYMPTOMS
In the UK, GPs will on average only diagnose one or two cases of
lung cancer per year (if they are in full-time practice).21 However,
during that year, GPs will see hundreds of patients with common
symptoms, such as cough, breathlessness and chest pain—hence,
there are signiﬁcant difﬁculties in identifying, diagnosing and
referring these patients in a timely manner.
The 2015 NICE lung cancer guidelines on recognition and
referral22 have underpinned some important strategies to
enhance timely lung cancer diagnosis; in many regions of the
UK, there are now accelerated diagnostic pathways that assist GPs
in identifying and referring patients appropriately.23 Audit data
demonstrate that there are typically several consultations prior to
a diagnosis of lung cancer being made.24 Evidence from
signiﬁcant event analysis in the UK has suggested that there is
timely recognition and referral of symptoms in primary care;25
longer intervals are typically attributed to factors such as X-rays
being reported as normal, patient-mediated factors and presenta-
tions complicated by co-morbidity. The importance of safety
netting has also been emphasised in presentations where a
diagnosis of lung cancer is possible.26
There needs to be continued work to counteract the ‘nihilism’
associated with lung cancer; PCPs are very well aware of patients
who may suspect they have lung cancer but fail to present either
because they blame themselves (through a history of smoking) or
because they believe that if a cancer is diagnosed there is little
that can be done about it.27 This, coupled with the tendency for
patients in the UK to be concerned about ‘bothering the doctor’,28
can have detrimental effects on early diagnosis.
While public campaigns can do much to overcome barriers to
presentation, it is vital that PCPs become more pro-active in
achieving more timely diagnosis in their practice populations. It is
been recommended that they should recognise the psychological
mechanisms that might underlie patient delay and tackle nihilistic
attitudes through educational and motivational strategies.29
Indeed, there is cause for cautious optimism with new treatments,
and this should be conveyed to patients; for example, the use of
stereotactic radiotherapy and volume-sparing surgery means that
patients who previously could not be offered curative treatment
due to co-morbidities are often now eligible.30
Audits that systematically identify at-risk patients who may be
failing to present are a potential way forward; interventions which
identify and target high-risk patients appear feasible in primary
care.31 Crucially, patients should be reassured that PCPs are always
happy to see them if they are worried about potential cancer
symptoms.
RISK ASSESSMENT AND LUNG CANCER
It is vital in assessing lung cancer risk to look carefully at lifestyle
factors and past medical history; only one in seven cases of lung
cancer occur in people who have never smoked, and the presence
of chronic obstructive pulmonary disease doubles the risk
independent of smoking history.32 A previous history of head
and neck, bladder and renal cancers and other factors such as
exposure to asbestos or living in high radon exposure areas are all
important in lung cancer risk assessment. Family history produces
an excess of risk and should be included in risk assessment—as
should the symptom of fatigue, a common feature of lung cancer.
Cancer decision support tools such as the ‘Caper’ instrument or ‘Q
cancer’ have emerged in recent years in the UK, enabling GPs to
make assessments of cancer risk based on presenting symp-
toms;33,34 they have been incorporated into clinical systems in
primary care with mixed results.
Beyond these symptom-based models, a number of lung cancer
risk models have been developed based on validated epidemio-
logical criteria—for example, the Liverpool Lung Project (LLP) risk
model35 (www.MyLungRisk.org), which was subsequently used in
the UK Lung Cancer Screening Trial.36 The LLPv2 risk model has
Fig. 1 Posters used in the ‘Be Clear on Cancer’ campaign
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also been used in the Liverpool Healthy Lung project,37 which has
accommodated the risk model within primary care practice and
produced risk assessments that are useful in clinical decision
making is now running into its third year. The Manchester lung
cancer pilot study38 has used the PLCO2012 risk prediction model
39
and the recent Yorkshire Lung cancer screening trial40 is using
both the LLPv2 and the PLCO2012 risk models. Models such as
these provide a systematic way of assessing lung cancer risk,
taking into account a range of factors, including smoking duration,
previous respiratory disease, family history of lung cancer, age,
previous history of malignancy and asbestos exposure.
Risk stratiﬁcation in primary care is clearly a key priority. We
need to look at instruments such as the LLP model and identify
ways that lung cancer risk stratiﬁcation can be made easy and
convenient in primary care. At present, it is not possible to
recommend a speciﬁc risk assessment tool for use in primary care;
current ongoing research in primary care is externally validating
existing tools and will compare their efﬁcacy.41 Acceptability and
feasibility also need to be examined; complex algorithms that
place extra burden on practitioners are unlikely to succeed.
However, we do need to ensure that the basic risk prediction
parameters are correctly documented in primary care, so they can
be utilised in any future national lung cancer screening
programme approved by the UKNSC. We also need a better
understanding of ways to maximise beneﬁts of these models—
while minimising potential harms such as over-medicalisation,
anxiety and false reassurance.42 Machine learning or neuro-
linguistic programming, whereby data from multiple practice-
based and external sources might be examined to develop risk
estimates, are also likely to play a signiﬁcant role in the future.43
DIAGNOSTIC PATHWAYS
Early diagnosis lung cancer clinics based on multi-disciplinary
teams (MDTs) are an ideal option for expediting diagnosis—ideally
with an urgent (2-week wait) referral;44 there is good evidence
that these specialist MDT clinics are associated with improved
outcomes. Another important consideration is involving the whole
primary care team and including other practitioners such as
pharmacists who see a lot of patients with, for example, repeat
purchases of cough medicine. There has been a push to change
referral practices in some parts of the UK—for example, to lower
the threshold that PCPs refer for chest X-ray45 and to encourage
practitioners to repeat the investigation after a few months if
symptoms persist; critically a normal chest X-ray does not exclude
diagnosis of lung cancer. One highly successful programme in
Leeds included the option for people to self-refer for chest X-rays
in walk-in clinics19—a crucial element was the engagement of
primary care in the design and implementation of the programme.
Diagnostic pathways have been closely examined and tested
over recent years, an example being CRUK’s ACE programme
(accelerate, coordinate and evaluate) initiated in June 2014 in
England and Wales.23 Patients often have complex pathways that
can lead to delays; important initiatives in the ACE programme
and elsewhere include risk-stratiﬁed computed tomographic (CT)
screening criteria for ‘straight to CT’ referrals following normal
chest X-rays and a focus on diagnostic paths for patients with
vague symptoms.
Work needs to continue on diagnostic pathways that might
expedite lung cancer diagnosis. It is important, for example, that
we get more evidence on the impact or potential impact of
direct access to investigations such as spiral CT from primary care
—at present, there is not sufﬁcient evidence or resource to
universally implement this strategy, and there is evidence that
delays can occur in primary care (for example, through ordering
too many chest X-rays.46 Nevertheless, GPs in the UK often
indicate that direct access to investigations would help stream-
line diagnosis.7
Idenfy paents 
at risk of 
developing lung 
cancer
Recruitment  
hard to reach
Smoking Cessaon 
as part of 
screening
Evidence for a 
validated screening 
test
Risk Predicon 
modeling (LLPv2,
PLCO2012)
Screen age range          
55–75 years
LDCT scan –
ulizing volume 
and VDT
Idenfy 
‘Indeterminate’ 
nodules  - Care 
Pathway
Referral to MDT in 
Center of Excellence-
Decision to treat –ﬁrst
opon Surgery / 
consider radiotherapy
Mortality data  
available for NLST  & 
NELSON
Cost eﬀecveness? 
NLST  $81K/ QALY:      
UKLS Modelling  
~£12k/QALY.
Annual or biennial 
repeat CTs?
Psychological 
impact?
Fig. 2 Levels of evidence for the implementation of lung cancer screening in Europe. The colour codes refer to the current status March 2019;
trafﬁc lights: green—ready, amber—borderline evidence. Underlined text indicates particular relevance for primary care53
D.P. Weller et al.
3
Published in partnership with Primary Care Respiratory Society UK npj Primary Care Respiratory Medicine (2019)    21 
LUNG CANCER SCREENING
A major challenge for primary care is the lack of symptoms in very
early stage lung cancer, highlighting the importance of examining
the potential of screening. The US National Lung Cancer Screening
Trial, which used low-dose CT scanning in high-risk patients,
showed a 20% reduction in lung cancer-speciﬁc mortality and
almost a 7% reduction in all-cause mortality—and the US
Preventive Task Force on Lung cancer Screening recommended
that lung cancer screening should be implemented in high-risk
populations.47,48 Accordingly, Medicare agreed to pay for lung
cancer screening within certain criteria—however, the current
uptake in the US is only ~2% of high-risk individuals.
The recent report on the NELSON trial at the World Lung Cancer
Conference, Toronto49 has demonstrated an encouragingly low
rate of false positives and a mortality beneﬁt of 26% in men and
between 39% and 61% in women—depending on the number of
years of follow-up (i.e. 8–10 years). These results provide further
impetus for the introduction of spiral CT scanning for individuals
at high risk of cancer in the UK. Figure 2 illustrates the process for
identifying an appropriate screening population, recruiting them
and implementing screening—in many ways more complex than
existing cancer screening programmes where recruitment is based
principally on age and gender.
If we are, indeed, on the cusp of a new screening programme,
there are important implications for primary care; the key issue in
lung cancer screening is identifying the right patients to invite.
This is a task that would involve primary care which currently lacks
the systems and the processes to undertake the kind of
population- based lung cancer risk assessment required. It is
important, therefore, that we plan for an era where high-risk
patients are screened for lung cancer (implemented, ideally, in
tandem with smoking cessation programmes). We should be
reﬁning current strategies to risk stratify patients in primary care in
preparation for this new era.50,51 Screening alone, however, is not
the total answer and a high level of awareness in both the public
and the primary care community will remain vital elements in
what needs to be a multi-pronged approach.52
CONCLUSIONS AND RECOMMENDATIONS
Mortality rates for lung cancer remain stubbornly high; if we are to
improve lung cancer outcomes, it is important that early diagnosis
and screening efforts achieve their maximum potential. We need
to:
● identify ways of raising awareness of symptoms potentially
associated with lung cancer in ways that encourage people at
higher risk to come forward—this will require reﬁnement of
the messages delivered in awareness-raising strategies
● counter the nihilistic beliefs often associated with lung cancer
—early diagnosis CAN lead to improved outcomes
● continually strive to improve the primary care response to
patients with symptoms of lung cancer, supported by better
diagnostic pathways and risk-based decision support
● identify ‘fail-safe’ mechanisms by which patients advised to
‘watch and wait’ are not lost to follow-up; it is vital that
patients understand these safety netting and follow-up advice
● ensure that the basic risk prediction parameters are correctly
documented in primary care, so they can be utilised in any
future national lung cancer screening programme approved
by the UKNSC
● reﬁne methods to implement lung cancer risk assessment
model approaches; this is key to improving diagnosis of early
lung cancer—and we should aim for risk estimates that can be
readily incorporated into the various kinds of practice software
used in primary care practices
● continue to improve diagnostic pathways; at present, many
different models are being evaluated, including those which
give primary care more direct access to investigations such as
spiral CT. The key task will be implementation and appropriate
support once the best models are determined
● fully engage primary care with the likely implementation of
spiral CT lung cancer screening in the next few years—this will
require the best possible risk-stratiﬁcation approaches to
ensure screening is directed at those who stand to beneﬁt the
most from it. It is vital that primary care rises to this challenge
Primary care needs to play a central role in efforts to diagnose
lung cancer earlier, if there is to be an improvement in lung cancer
outcomes in the years ahead. Research over the past decade gives
us a much clearer idea of what needs to be done in reﬁning
primary care-based strategies; with adequate commitment and
resources primary care will, in conjunction with other health care
sectors, help reduce the burden from this disease.
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